Twist Bioscience (TWST) Receivables - Net (2018 - 2026)

Twist Bioscience has disclosed Receivables - Net across 9 years of filings, most recently posting $64.2 million for Q1 2026.

• In Q1 2026, Receivables - Net rose 28.44% year-over-year to $64.2 million; the TTM figure through Mar 2026 stood at $64.2 million (up 28.44% YoY), while the FY2025 annual figure was $57.0 million, up 63.36% from the prior year.
• Receivables - Net improved to $64.2 million in Q1 2026, from $50.1 million in the prior quarter.
• Over the last five years, Receivables - Net for TWST reached as high as $64.2 million in Q1 2026 and fell as low as $32.0 million in Q2 2024.
• The 5-year median for Receivables - Net is $42.6 million (2023), against an average of $43.8 million.
• Annual changes were most pronounced in 2024 — Receivables - Net dropped 25.31% — and 2025, when it soared 63.36%.
• A 5-year view of Receivables - Net shows it stood at $44.4 million in 2022, then fell by 20.44% to $35.4 million in 2023, then advanced by 11.2% to $39.3 million in 2024, then increased by 27.34% to $50.1 million in 2025, then grew by 28.15% to $64.2 million in 2026.
• According to Business Quant data, Receivables - Net over the past three periods registered $64.2 million, $50.1 million, and $57.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.